Venture Life Group PLC (LON:VLG)‘s stock had its “buy” rating reaffirmed by equities research analysts at Panmure Gordon in a report issued on Monday. They currently have a GBX 128 ($1.58) target price on the stock. Panmure Gordon’s price target would indicate a potential upside of 141.51% from the company’s current price.

Separately, Beaufort Securities reissued a “speculative buy” rating on shares of Venture Life Group PLC in a research note on Thursday, September 22nd.

Shares of Venture Life Group PLC (LON:VLG) opened at 51.00 on Monday. Venture Life Group PLC has a 1-year low of GBX 43.00 and a 1-year high of GBX 81.92. The stock has a 50 day moving average of GBX 51.61 and a 200 day moving average of GBX 55.77. The company’s market cap is GBX 18.78 million.

About Venture Life Group PLC

Venture Life Group PLC is a United Kingdom-based consumer self-care company. The Company focuses on developing, manufacturing and commercializing products for the ageing population. Its product range includes medical devices (such as those for minor aches and pains, and alleviating symptoms associated with hemorrhoids and itchy skin), food supplements (such as those for lowering cholesterol and improving brain function), and dermo-cosmetics and cosmetics for addressing the signs of skin-ageing.

Receive News & Ratings for Venture Life Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venture Life Group PLC and related companies with's FREE daily email newsletter.